Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BDP).

Read more

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics S.A., announced today positive outcome from its planned, prespecified interim analysis of its Phase 2b trial, PORTICO, with vafidemstat for borderline personality disorder (BPD). These...

Read more

ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder

by Oryzon Genomics

PORTICO (EudraCT No.: 2020-003469-20, ClinicalTrials.gov Identifier NCT04932291) is a multicenter, double-blind, randomized, placebo-controlled, Phase IIb trial to evaluate the efficacy and safety of ...

Read more

ORYZON to hold multiple corporate activities in January

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON to present new clinical data and corporate updates at international conferences in November and December

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON reports results and corporate update for quarter ended September 30, 2021

by Oryzon Genomics

​Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today report...

Read more

ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today...

Read more

Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

ORYZON reports results and corporate update for first half ended June 30, 2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

El microARN circulante podría ayudar a ...

by Hospital de la Santa Creu i Sant Pau

Un estudio realizado en el Instituto de Investigación del Hospital de...

Photos Stream